Ontology highlight
ABSTRACT:
SUBMITTER: Menke-van der Houven van Oordt CW
PROVIDER: S-EPMC4745807 | biostudies-other | 2015 Oct
REPOSITORIES: biostudies-other
Menke-van der Houven van Oordt Catharina Willemien CW Gootjes Elske C EC Huisman Marc C MC Vugts Danielle J DJ Roth Chantal C Luik Anne Marije AM Mulder Emma R ER Schuit Robert C RC Boellaard Ronald R Hoekstra Otto S OS van Dongen Guus Ams GA Verheul Henk M W HM
Oncotarget 20151001 30
Monoclonal antibodies (mAbs) against the epidermal growth factor receptor (EGFR) are used in the treatment of advanced colorectal cancer (mCRC). Approximately 50% of patients benefit despite patient selection for RAS wild type (wt) tumors. Based on the hypothesis that tumor targeting is required for clinical benefit of anti-EGFR treatment, biodistribution and tumor uptake of (89)Zr-cetuximab by Positron Emission Tomography (PET), combining the sensitivity of PET with the specificity of cetuximab ...[more]